Hypothesis

Oral NAD+ precursors (NMN or NR) will raise SIRT1 deacetylase activity in human peripheral blood mononuclear cells (PBMCs) only when administered alongside a fasting‑mimicking diet (FMD) that induces the NAD+ salvage enzyme NAMPT.

Mechanistic Rationale

• NAD+ precursors increase circulating NAD+ pools, but SIRT1 activation requires locally generated NAD+ within nuclear or mitochondrial microdomains where the enzyme resides.
• NAMPT catalyzes the rate‑limiting step of the NAD+ salvage pathway, producing NAD+ from nicotinamide; its activity is acutely upregulated by AMP‑activated protein kinase (AMPK) during energy stress such as fasting.
• In mice, AMPK‑driven NAMPT expression creates a permissive NAD+ milieu that allows SIRT1 to engage targets like PGC‑1α; without this boost, excess NAD+ remains largely cytosolic and fails to stimulate SIRT1.
• Human data show that NMN/NR reliably elevate blood NAD+ (1, 6) but no study has measured SIRT1 activity in accessible tissues after precursor supplementation alone.
• FMDs (5‑day low‑calorie cycles) activate AMPK and increase NAMPT transcription in human immune cells (3), providing a testable condition to couple precursor availability with enzyme‑driven NAD+ production.

Testable Predictions

1. Baseline: PBMC NAD+ levels rise ~2‑fold after 2 weeks of NMN or NR monotherapy; SIRT1 activity (measured by PGC‑1α deacetylation) remains unchanged.
2. FMD‑only: A 5‑day FMD increases NAMPT mRNA and protein in PBMCs (~1.5‑fold) and modestly elevates SIRT1 activity (~1.3‑fold) without altering total NAD+.
3. Combined: NMN/NR plus concurrent FMD yields a synergistic increase in PBMC NAD+ (>2.5‑fold) and a significant rise in SIRT1 activity (>1.8‑fold) relative to either intervention alone.
4. Inhibition: Co‑administration of the NAMPT inhibitor FK866 (at a dose that reduces intracellular NAD+ by ~30 % in vitro) abolishes the SIRT1 activity boost seen with the combined regimen, confirming NAMPT dependence.

Experimental Design (outline)

• Participants: Healthy middle‑aged adults (40‑65 y), stratified by sex, n = 40 per arm.
• Arms: (A) Placebo, (B) NMN 250 mg d⁻¹, (C) NR 300 mg d⁻¹, (D) FMD alone (5 days/month), (E) NMN + FMD, (F) NR + FMD, (G) NMN + FMD + FK866 (low dose), (H) NR + FMD + FK866.
• Duration: 8 weeks, with FMD cycles at weeks 2, 4, 6.
• Outcomes: fasting blood NAD+ (LC‑MS), PBMC NAMPT protein (Western blot), SIRT1 activity (PGC‑1α deacetylation ELISA), downstream markers (phospho‑ACC, mitochondrial DNA copy number).
• Analysis: Two‑way ANOVA (supplement × fasting) with post‑hoc tests; synergy defined as interaction term p < 0.05 and effect size exceeding the sum of individual effects.

Falsifiability

If the combined NMN/NR + FMD condition fails to produce a statistically significant increase in SIRT1 activity beyond that seen with either monotherapy, or if NAMPT inhibition does not attenuate this effect, the hypothesis is refuted. Conversely, a demonstrable, NAMPT‑dependent rise in SIRT1 activity would substantiate the mechanistic link between fasting‑induced salvage capacity and NAD+ precursor efficacy in humans.